RxDoctor Payments Data

Chantal Trice

Family · Greensburg, PANPI 1821254038

Payments from drug & device makers

$551in general payments, 2019–2025

Across 23 payments — averaging $23.95 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Atricure, Inc.$142
  • AstraZeneca$135
  • Novo Nordisk$90
  • Cvrx, Inc.$83
  • Medtronic$36
  • Novartis$28
  • plus $36 from 3 others

What the payments were for

  • Food & beverage$44080%
  • Education$11120%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$551 in reported general payments places this provider in the 60th percentile of 4,717 family providers in Pennsylvania.

See all family providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$45,666
Medicare patients
380
Services billed
490

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban1,267$1,093,126
EntrestoSacubitril/Valsartan326$327,300
XareltoRivaroxaban295$282,884
Repatha SureclickEvolocumab265$187,969
FarxigaDapagliflozin Propanediol172$156,248
JardianceEmpagliflozin120$107,536
MultaqDronedarone Hcl40$60,092
BrilintaTicagrelor69$48,549
Repatha SyringeEvolocumab66$37,992
Atorvastatin Calcium1,115$12,435
Praluent PenAlirocumab13$12,013
Metoprolol Succinate796$11,123
Ezetimibe376$10,288
Rosuvastatin Calcium872$9,970
Dofetilide33$6,742

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
NovartisEntresto$28$327,300326 claims
AstraZenecaFarxiga, Brilinta$135$204,796241 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 4,717 family providers in Pennsylvania.

Other family in Greensburg

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →